The Primary Care Companion for CNS Disorders

CME Institute

Home | About Us | Mission Statement | All CME Activities | MyCME | CME Facebook | CME Twitter

JCP

Home | About JCP | Subscribe | Archive | Information for Authors | Information for Reviewers | Information for Advertisers | CNS Job Market | Customer Service | JCP Facebook | JCP Twitter

PCC

Home | About PCC | Register | Archive | Information for Authors | Information for Reviewers | PCC Facebook | PCC Twitter

Help

FAQ | About Psychiatrist.com | Terms of use | Privacy policy

magnifying glass for search

  • magnifying glass for search
  • Advanced Search

Login

Login  
Login | Login Help | Register | Subscribe
Register | Elerts

Quick Links

Font: A | A | A

Top

Purchase PDF

Vol 14, No 1
Table of Contents

Facebook ShareShare

twitter shareTweet This

envelope iconEmail a link

Related ►

Related Articles

[X]

<p class="frontmatter-fieldnotes disclaimernew" style="margin-bottom:15px;">This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s <a href="/pages/termsofuse.aspx" target="_blank">Terms & Conditions</a>.</p> <div id="x12lcx01362">
<div class="story">
<p class="ltrs-br-ltr-br-title"><span class="bold">Correction</span></p>
<p class="ltrs-br-ltr-br-body-text"><span class="bold">Dear Reader:</span> In the article “Managing Anticholinergic Side Effects” by Joseph A. Lieberman, III, MD, MPH (<span class="hyperlink"><a href="/PCC/article/PublishingImages/2012/v14n01/12lcx01362/v06s0204.pdf" target="_top">Prim Care Companion J Clin Psychiatry 2004;6[suppl 2]:20–23</a></span>), the erroneous statement was made on page 23 that atropine can be used to treat anticholinergic delirium symptoms. A reader alerted us to this error and correctly notes that atropine is a potent anticholinergic agent that would worsen symptoms. This sentence has been removed from the online version of the article at<span class="italic"> PCC</span>’s Web site. </p>
<p class="ltrs-br-ltr-br-body-text">If anticholinergic poisoning is suspected (eg, related to overdose, usually with multiple medications including psychoactive ones), a poison control center should be consulted (United States Poison Control Network at 1-800-222-1222 or an international center <span class="hyperlink"><a href="http://www.who.int/gho/phe/chemical_safety/poisons_centres/en/">http://www.who.int/gho/phe/chemical_safety/poisons_centres/en/</a></span>). </p>
<p class="ltrs-br-ltr-br-body-text">Diagnosis is critical since other conditions including serotonin syndrome may mimic several, though not all, of the classic symptoms of anticholinergic poisoning. The classic symptoms include the Alice in Wonderland constellation of “dry as a bone” (anhidrosis from interference with sweat gland innervation), “red as a beet” (cutaneous vasodilation compensating for the loss of sweat production), “hot as a hare” (anhidrotic hyperthermia), “full as a flask” (urinary retention from anticholinergic reduction of detrusor contraction reducing the urge to urinate and preventing normal opening of the urethral sphincter), “blind as a bat” (nonreactive mydriasis, anticholinergic medications produce pupillary dilation and ineffective accommodation that frequently manifests as blurry vision), and “mad as a hatter” (delirium, hallucinations, anxiety, agitation, dysarthria, disorientation, visual hallucinations, bizarre behavior, delirium, psychosis, coma, and seizures). While serotonin syndrome may cause agitation, tachycardia, and hyperthermia, it usually can be differentiated from anticholinergic toxicity since it causes diaphoresis with profuse sweating. Salicylate overdose may cause hyperthermia and altered mental status, but not other classic symptoms. </p>
<p class="ltrs-br-ltr-br-body-text">Treatment of anticholinergic poisoning generally involves decontamination (use of activated charcoal in alert patients) and treatment of hyperthermia and of any cardiac rhythm abnormalities (prolonged QRS or QT). Agitation may be controlled with benzodiazepines. If both physical and mental symptoms of poisoning are significant, physostigmine, which crosses the blood-brain barrier, may be considered as an antidote. No large study has evaluated its efficacy and safety in such use. It should not be used in related conditions such as tricyclic overdose since it has led to asystole in case reports. When physostigmine is administered, cardiac monitoring should be in place, and atropine and resuscitative equipment should be immediately available. Again, given the infrequent use of physostigmine in most settings, consultation with a poison control center is recommended before initiating such therapy.</p>
<p class="ltrs-br-ltr-br-author"><span class="bold">Larry Culpepper, MD, MPH</span></p>
<p class="ltrs-br-ltr-br-author">Editor in Chief</p>
<p class="ltrs-br-ltr-br-author"><span class="bold">Joseph A. Lieberman, III, MD, MPH</span></p>
</div>
</div>
Manage Subscriptions
/_layouts/images/ReportServer/Manage_Subscription.gif
/PCC/article/_layouts/ReportServer/ManageSubscriptions.aspx?list={ListId}&ID={ItemId}
0x80
0x0
FileType
rdl
350
Manage Data Sources
/PCC/article/_layouts/ReportServer/DataSourceList.aspx?list={ListId}&ID={ItemId}
0x0
0x20
FileType
rdl
351
Manage Shared Datasets
/PCC/article/_layouts/ReportServer/DatasetList.aspx?list={ListId}&ID={ItemId}
0x0
0x20
FileType
rdl
352
Manage Parameters
/PCC/article/_layouts/ReportServer/ParameterList.aspx?list={ListId}&ID={ItemId}
0x0
0x4
FileType
rdl
353
Manage Processing Options
/PCC/article/_layouts/ReportServer/ReportExecution.aspx?list={ListId}&ID={ItemId}
0x0
0x4
FileType
rdl
354
Manage Cache Refresh Plans
/PCC/article/_layouts/ReportServer/CacheRefreshPlanList.aspx?list={ListId}&ID={ItemId}
0x0
0x4
FileType
rdl
355
View Report History
/PCC/article/_layouts/ReportServer/ReportHistory.aspx?list={ListId}&ID={ItemId}
0x0
0x40
FileType
rdl
356
View Dependent Items
/PCC/article/_layouts/ReportServer/DependentItems.aspx?list={ListId}&ID={ItemId}
0x0
0x4
FileType
rsds
350
Edit Data Source Definition
/PCC/article/_layouts/ReportServer/SharedDataSource.aspx?list={ListId}&ID={ItemId}
0x0
0x4
FileType
rsds
351
View Dependent Items
/PCC/article/_layouts/ReportServer/DependentItems.aspx?list={ListId}&ID={ItemId}
0x0
0x4
FileType
smdl
350
Manage Clickthrough Reports
/PCC/article/_layouts/ReportServer/ModelClickThrough.aspx?list={ListId}&ID={ItemId}
0x0
0x4
FileType
smdl
352
Manage Model Item Security
/PCC/article/_layouts/ReportServer/ModelItemSecurity.aspx?list={ListId}&ID={ItemId}
0x0
0x2000000
FileType
smdl
353
Regenerate Model
/PCC/article/_layouts/ReportServer/GenerateModel.aspx?list={ListId}&ID={ItemId}
0x0
0x4
FileType
smdl
354
Manage Data Sources
/PCC/article/_layouts/ReportServer/DataSourceList.aspx?list={ListId}&ID={ItemId}
0x0
0x20
FileType
smdl
351
Load in Report Builder
/PCC/article/_layouts/ReportServer/RSAction.aspx?RSAction=ReportBuilderModelContext&list={ListId}&ID={ItemId}
0x0
0x2
FileType
smdl
250
Edit in Report Builder
/_layouts/images/ReportServer/EditReport.gif
/PCC/article/_layouts/ReportServer/RSAction.aspx?RSAction=ReportBuilderReportContext&list={ListId}&ID={ItemId}
0x0
0x4
FileType
rdl
250
Edit in Report Builder
/PCC/article/_layouts/ReportServer/RSAction.aspx?RSAction=ReportBuilderDatasetContext&list={ListId}&ID={ItemId}
0x0
0x4
FileType
rsd
250
Manage Caching Options
/PCC/article/_layouts/ReportServer/DatasetCachingOptions.aspx?list={ListId}&ID={ItemId}
0x0
0x4
FileType
rsd
350
Manage Cache Refresh Plans
/PCC/article/_layouts/ReportServer/CacheRefreshPlanList.aspx?list={ListId}&ID={ItemId}&IsDataset=true
0x0
0x4
FileType
rsd
351
Manage Data Sources
/PCC/article/_layouts/ReportServer/DataSourceList.aspx?list={ListId}&ID={ItemId}
0x0
0x20
FileType
rsd
352
View Dependent Items
/PCC/article/_layouts/ReportServer/DependentItems.aspx?list={ListId}&ID={ItemId}
0x0
0x4
FileType
rsd
353
Compliance Details
javascript:commonShowModalDialog('{SiteUrl}/_layouts/itemexpiration.aspx?ID={ItemId}&List={ListId}', 'center:1;dialogHeight:500px;dialogWidth:500px;resizable:yes;status:no;location:no;menubar:no;help:no', function GotoPageAfterClose(pageid){if(pageid == 'hold') {STSNavigate(unescape(decodeURI('{SiteUrl}'))+'/_layouts/hold.aspx?ID={ItemId}&List={ListId}'); return false;} if(pageid == 'audit') {STSNavigate(unescape(decodeURI('{SiteUrl}'))+'/_layouts/Reporting.aspx?Category=Auditing&backtype=item&ID={ItemId}&List={ListId}'); return false;} if(pageid == 'config') {STSNavigate(unescape(decodeURI('{SiteUrl}'))+'/_layouts/expirationconfig.aspx?ID={ItemId}&List={ListId}'); return false;}}, null); return false;
0x0
0x1
ContentType
0x01
898
Document Set Version History
javascript:SP.UI.ModalDialog.ShowPopupDialog('{SiteUrl}/_layouts/DocSetVersions.aspx?List={ListId}&ID={ItemId}')
0x0
0x0
ContentType
0x0120D520
330
Send To other location
javascript:GoToPage('{SiteUrl}/_layouts/docsetsend.aspx?List={ListId}&ID={ItemId}')
0x0
0x0
ContentType
0x0120D520
350

Information Links

Terms of Use | Privacy Policy | Information for Authors (JCP) | Information for Authors (PCC) | Reprints and Permissions | CNS Job Market | Information for Advertisers | Media Relations | PPP COVID-19 Statement

Help

Contact us | Unsubscribe from Elerts | Customer Service | FAQ | About JCP | About PCC | About Psychiatrist.com

Our Family of Sites

Psychiatrist.com | The Journal of Clinical Psychiatry | The Primary Care Companion | The CME Institute | Strong Veterans
Anonymous